Literature DB >> 23017810

Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone.

Heike E Künzel1, Konstantina Apostolopoulou, Anna Pallauf, Sabine Gerum, Katrin Merkle, Sebastian Schulz, Evelyn Fischer, Volker Brand, Martin Bidlingmaier, Stephan Endres, Felix Beuschlein, Martin Reincke.   

Abstract

Psychopathological symptoms in patients with primary aldosteronism (PA) have been reported. In a cross-sectional design the self-reported physical and mental condition among patients with PA of the German Conn's Registry differently treated during the course of the disease were analysed. 27 patients were investigated before initiation of specific therapy (U), 56 patients were on chronic mineralocorticoid antagonist treatment (MRA) and 49 patients had undergone adrenalectomy (ADX). Patient's quality of life was analysed with the SF-12 for a Physical (PCS) and a Mental Component (MCS). Statistically significant lower scores for PCS were found for female PA patients treated with MRA in comparison to ADX patients and the German reference population (36.4 ± 11.1 vs. 49.1 ± 10.9 (p = 0.024) vs. 47.9 ± 9.7 (p = 0.001)), respectively. Concerning MCS, untreated female patients scored significantly lower (36.5 ± 7.4) than females from the German population (51.3 ± 8.4, p = 0.000). Furthermore, untreated females appear to differ significantly from MRA and ADX females, scoring the lowest reading (U vs. MRA: p = 0.029; U vs. ADX: p = 0.005). Significant correlations were found between plasma aldosterone (r = -0.819, p = 0.013) and the MCS and between plasma renin concentration and MCS (r = -0.938, p = 0.001) in female MRA patients. In summary, PA patients report a worse physical and mental condition than the one reported for the German reference population. Untreated and mineralocorticoid antagonist treated patients report the lowest readings. Females were found to be more impaired than males in QoL. MRA treatment seems to affect the MCS of female patients.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017810     DOI: 10.1016/j.jpsychires.2012.08.025

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  15 in total

1.  Outcome of surgical treatment of primary aldosteronism.

Authors:  Marilisa Citton; Giovanni Viel; Gian Paolo Rossi; Franco Mantero; Donato Nitti; Maurizio Iacobone
Journal:  Langenbecks Arch Surg       Date:  2015-01-08       Impact factor: 3.445

Review 2.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 3.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 4.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

5.  Prevalence of primary aldosteronism in primary care: a cross-sectional study.

Authors:  Sabine C Käyser; Jaap Deinum; Wim Jc de Grauw; Bianca Wm Schalk; Hans Jhj Bor; Jacques Wm Lenders; Tjard R Schermer; Marion Cj Biermans
Journal:  Br J Gen Pract       Date:  2018-01-15       Impact factor: 5.386

Review 6.  Primary aldosteronism.

Authors:  Sean M Wrenn; Anand Vaidya; Carrie C Lubitz
Journal:  Gland Surg       Date:  2020-02

7.  Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.

Authors:  Carrie C Lubitz; Konstantinos P Economopoulos; Stephen Sy; Colden Johanson; Heike E Kunzel; Martin Reincke; G Scott Gazelle; Milton C Weinstein; Thomas A Gaziano
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-11-10

8.  Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists.

Authors:  Yuichi Yoshida; Rika Yoshida; Kanako Shibuta; Yoshinori Ozeki; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Hirotaka Shibata
Journal:  J Endocr Soc       Date:  2021-02-16

9.  Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism.

Authors:  Marilisa Citton; Giovanni Viel; Francesca Torresan; Gian Paolo Rossi; Maurizio Iacobone
Journal:  BMC Surg       Date:  2019-04-24       Impact factor: 2.102

10.  A disease-specific Quality of Life questionnaire for primary aldosteronism.

Authors:  Marieke Stientje Velema; Aline de Nooijer; Ad R M M Hermus; Henri J L M Timmers; Jacques W M Lenders; Olga Husson; Jaap Deinum
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.